Targeted Disease(s):
Lung Cancer

Purpose of Study:

To compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Study Dates:
January 1, 2021 - July 1, 2022

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Takeda

ClinicalTrails.gov Identifier:
NCT04129502

Register for Trial
Freedom From Smoking | Virtual Training
, | Aug 04, 2021
Freedom From Smoking Facilitator Training
, | Aug 11, 2021